JUNB/AP-1 controls IFN-γ during inflammatory liver disease

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5258-5268

  Thomsen, Martin K ^a   Bakiri, Latifa ^a   Hasenfuss, Sebastian C ^a   Hamacher, Rainer ^a   Martinez, Lola ^b   Wagner, Erwin F ^a  

^a F BBVA Cancer Cell Biology Programme   (United States)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CONCANAVALIN A; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIVER CELL; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; CELL DEATH; CONCANAVALIN A; DRUG-INDUCED LIVER INJURY; GALACTOSYLCERAMIDES; HEPATITIS; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; POLY I-C; RECOMBINANT FUSION PROTEINS; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC;

EID: 84890056439     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70405     Document Type: Article

References (61)

1. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol. 2013;7(2):206-223
2. Herkel J, Schuchmann M, Tiegs G, Lohse AW. Immune-mediated liver injury. J Hepatol. 2005; 42(6):920-923
3. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology. 2012;56(4):1567-1574
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-2576
5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-229
6. Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975-990
7. Zhang SY, et al. Inborn errors of interferon (IFN)- mediated immunity in humans: insights into the respective roles of IFN-α/β, IFN-γ, and IFN-λ in host defense. Immunol Rev. 2008;226:29-40
8. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44-53
9. Agnello D, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147-161
10. Schoenborn JR, Wilson CB. Regulation of interferon-γ during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101
11. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000;192(7):921-930
12. Zeissig S, et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med. 2012;18(7):1060-1068
13. Ishikawa T. Immunoregulation of hepatitis B virus infection-rationale and clinical application. Nagoya J Med Sci. 2012;74(3-4):217-232
14. Horras CJ, Lamb CL, Mitchell KA. Regulation of hepatocyte fate by interferon-gamma. Cytokine Growth Factor Rev. 2011;22(1):35-43
15. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868
16. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005;208:126-140
17. Cippitelli M, et al. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem. 1995;270(21):12548-12556
18. Rincon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 1994;13(18):4370-4381
19. Wisniewska MB, Ameyar-Zazoua M, Bakiri L, Kaminska B, Yaniv M, Weitzman JB. Dimer composition and promoter context contribute to functional cooperation between AP-1 and NFAT. J Mol Biol. 2007;371(3):569-576
20. Li B, Tournier C, Davis RJ, Flavell RA. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J. 1999; 18(2):420-432
21. Meixner A, Karreth F, Kenner L, Wagner EF. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J. 2004;23(6):1325-1335
22. Guinea-Viniegra J, et al. TNFα shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev. 2009;23(22):2663-2674
23. Meixner A, et al. Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol. 2008;10(8):1003-1011
24. Passegue E, Jochum W, Behrens A, Ricci R, Wagner EF. JunB can substitute for Jun in mouse devel-opment and cell proliferation. Nat Genet. 2002; 30(2):158-166
25. Hasselblatt P, Rath M, Komnenovic V, Zatloukal K, Wagner EF. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104(43):17105- 17110
26. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 1992;90(1):196-203
27. Schumann J, et al. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol. 2000;157(5):1671-1683
28. Matsuoka S, et al. A monoclonal antibody to the alpha2 domain of murine major histocompatibility complex class 1 that specifically kills activated lymphocytes and blocks liver damage in the concanavalin A hepatitis model. J Exp Med. 2003; 198(3):497-503
29. Nakashima H, et al. Superoxide produced by Kupffer cells is an essential effector in concanavalin A-induced hepatitis in mice. Hepatology. 2008;48(6):1979-1988
30. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97(10):5498-5503
31. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity. 2003;19(5):725-737
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001; 413(6857):732-738
33. Zhang M, et al. The β2 integrin CD11b attenuates polyinosinic:polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions. Hepatology. 2009;50(5):1606-1616
34. Shimosaka A. Role of NKT cells and alpha-galactosyl ceramide. Int J Hematol. 2002;76(suppl 1):277-279
35. Biburger M, Tiegs G. α-Galactosylceramideinduced liver injury in mice is mediated by TNF-α but independent of Kupffer cells. J Immunol. 2005; 175(3):1540-1550
36. Cao Z, Dhupar R, Cai C, Li P, Billiar TR, Geller DA. A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by α-galactosylceramide. J Immunol. 2010;185(4):2536-2543
37. Hayashi T, Ishida Y, Kimura A, Iwakura Y, Mukaida N, Kondo T. IFN-γ protects cerulein-induced acute pancreatitis by repressing NF-κB activation. J Immunol. 2007;178(11):7385-7394
38. Hou J, Schindler U, Henzel WJ, Wong SC, Mc Knight SL. Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity. 1995;2(4):321-329
39. Shuai K, Schindler C, Prezioso VR, Darnell JE. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science. 1992;258(5089):1808-1812
40. Klein C, et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest. 2005;115(4):860-869
41. Naka T, et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity. 2001;14(5):535-545
42. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol. 2001;69(4):598-604
43. Hiroi M, Ohmori Y. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-κB for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-γ gene. J Biol Chem. 2003;278(1):651-660
44. Tsuge M, et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS One. 2011;6(8):e23856
45. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003;39(3):333-340
46. Koo GC, Gan YH. The innate interferon gamma response of BALB/c and C57BL/6 mice to in vitro Burkholderia pseudomallei infection. BMC Immunol. 2006;7:19
47. Garaude J, et al. SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol. 2008;180(9):5983-5990
48. Biron CA, Young HA, Kasaian MT. Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med. 1990;171(1):173-188
49. Shi M, Lin TH, Appell KC, Berg LJ. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity. 2008;28(6):763-773
50. Eferl R, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112(2):181-192
51. Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000;6(5):1109-1119
52. Chen T, Zamora R, Zuckerbraun B, Billiar TR. Role of nitric oxide in liver injury. Curr Mol Med. 2003; 3(6):519-526
53. Xu W, et al. STAT-1 and c-Fos interaction in nitric oxide synthase-2 gene activation. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L137-L148
54. Gough DJ, et al. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon γ response genes. J Biol Chem. 2007;282(2):938-946
55. Erhardt A, et al. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J Immunol. 2011; 186(9):5284-5293
56. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ. Induction of hepatitis by JNK-mediated expression of TNF-α. Cell. 2009;136(2):249-260
57. Gale MJ, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230(2):217-227
58. Critchley-Thorne RJ, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009;106(22):9010-9015
59. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013; 138(2):105-115
60. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239-252
61. Braumuller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013; 494(7437):361-365